Message #21 From:
NewsBot Date: November 3, 2006 02:28:00 PM
CYGX News CytoGenix Signs Contract for Design/Build Development of New Plant and Office Facility
HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (OTCBB:CYGX) announces the conclusion of
negotiations with GSL Constructors, Ltd for the design/build development
of a $3.8 million, 20,000 sq. ft. facility in Houston’s
Westchase District. The building will be located on a two and one-third
acre site in the Oak Park at Westchase office park and constructed by GSL’s
affiliate, Kingham Dalton Wilson whose experience spans over 110 years
and 1,000 projects. CytoGenix plans to occupy the building in the fourth
quarter of 2007.
The new facility will be the company’s
headquarters and provide the space for growth and expansion of DNA
manufacturing capacity. The building will contain approximately 8,000
sq. ft. of state-of-the-art, GMP-qualified clean-room space for
production of clinical-grade synDNA™, the
company’s proprietary synthesized DNA. This
area will house several production suites with capacity to produce 50
grams of high purity DNA daily.
Dr. Malcolm H. Skolnick, CytoGenix President and CEO, commented, “This
is a very important step in the evolution of our company and bringing
increasing value to our shareholders. This investment will allow us to
manufacture GMP grade material for our synDNA™
influenza vaccines and for our herpes antiviral product Simplivir™,
as well as, supplying a growing market for clinical grade DNA. Once
fully staffed, this facility will employ approximately 200 scientists,
technicians and other professionals. We are very happy to make this
contribution to Houston’s economic development.”
Mr. Welcome Wilson, Jr., President of GSL, stated, “One
of the best things about my job is that I get to know and work with many
different kinds of businesses. I’m excited
about the promise and the potential of the biotech industry in Houston
and about CytoGenix in particular.” Brad
Berry of GSL added, “We view our clients as
partners and as such will deliver a premium product on time.”
About CytoGenix, Inc.: CytoGenix, Inc. is a Houston-based
biopharmaceutical company that develops and markets innovative products
and services based on its proprietary ssDNA expression technology. The
company has developed a breakthrough synthetic process for large-scale
production of high purity DNA at a fraction of the cost of traditional
fermentation methods. CytoGenix currently has one issued US patent and
47 international or US pending patent applications claiming methods and
materials in connection with this platform technology.
About GSL: GSL is a Design/Build Developer of single tenant
facilities. GSL has developed over 100 facilities in the Houston area
since 1998 and owns over 60 facilities as Landlord. Kingham Dalton
Wilson has recently completed two other laboratory facilities and a
financial center in the Westchase area and currently has other projects
under construction throughout the Houston area.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition, and
other factors more fully detailed in the company's filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology is found on the website at www.cytogenix.com.
